Doctor/Patient Portal Login

Doctor

Retina Specialist Comprehensive Ophthalmologist Optometrist

Remote Monitoring Center
Patient Referral & Data Access
Implementation

Remote Monitoring Technology

The Device
The Test

Coverage Information

Need for Early Detection
Current Standard of Care
The ForeseeHome Solution

Clinical Presentations

ForeseeHome NRich Registry

The Evolution of AMD Patient Management: A 3-Part Video Series

Ordering ForeseeHome

ForeseeHome Program Overview

Eye Care Professional Portal

Marketing Your Practice

Upcoming Events

Resource Library

Resource Library Share

Topic

Upcoming Events

FDA-Cleared

Medicare-Covered

Easy to Use

Want the latest ForeseeHome news and updates?

Sign up for our monthly email newsletter to stay up to date.

Email Address

We care about the protection of your data. Read our Privacy Policy.

The Program Remote Monitoring Technology Coverage Information

Web Privacy Policy Notice of Information Practices

Monitoring Center

Contact Notal Vision

FDA Indications for Use

ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration, as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

The ForeseeHome AMD Monitoring Program is available by prescription only and should be used in addition to the doctor's recommended care program.

The ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with intermediate dry AMD who are at risk of developing wet AMD.

ForeseeHome is a registered trademark, and the ForeseeHome AMD Monitoring Program and logo and the Notal Vision logo are trademarks of Notal Vision.

© 2025 Notal Vision, Inc. All rights reserved.